# Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

> **NCT05193578** · PHASE2 · COMPLETED · sponsor: **Jan Frystyk** · enrollment: 154 (actual)

## Conditions studied

- Schizophrenia
- Prediabetic State

## Interventions

- **DRUG:** Semaglutide, 1.34 mg/mL
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05193578
- **Lead sponsor:** Jan Frystyk
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-03-18
- **Final completion:** 2024-05-01
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193578, "Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05193578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*